1-氨基-3-(四氢-2H-吡喃-2-基氧基)-2-丙醇 | 762241-39-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 中文名称: 1-氨基-3-(四氢-2H-吡喃-2-基氧基)-2-丙醇
• 英文名称: 1-amino-3-(tetrahydro-2H-pyran-2-yloxy)propan-2-ol
• 英文别名: 2-Propanol, 1-amino-3-[(tetrahydro-2H-pyran-2-YL)oxy]-；1-amino-3-(oxan-2-yloxy)propan-2-ol
• CAS: 762241-39-4
• 化学式: C₈H₁₇NO₃
• 分子量: 175.228
• InChiKey: VUZVNKPIFYKGTK-UHFFFAOYSA-N

物化性质

• 沸点：
  329.8±42.0 °C(Predicted)
• 密度：
  1.11±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  64.7
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099

反应信息

• 作为反应物：
  描述：

  1-氨基-3-(四氢-2H-吡喃-2-基氧基)-2-丙醇 在 草酰氯 、 二甲基亚砜 、 三乙胺 作用下， 以 二氯甲烷 、 氯仿 为溶剂， 反应 30.0h， 生成 1-(6,7-dimethyl-3-chloroquioxalin-2-ylamino)-3-(tetrahydro-2H-pyran-2-yloxy)propan-2-one
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 4-alkylamino-1-hydroxymethylimidazo[1,2-a]quinoxalines as adenosine A1 receptor antagonists

  摘要：

  A series of 4-alkylamino-1-hydroxymethylimidazo[1,2-a]quinoxalines have been synthesized and evaluated for their adenosine A(1) receptor inhibitory activity in the radioligand binding assays. The compounds were tested for the inhibition percent (IP) and the affinity toward A(1)AR (K-i) that IP were more than 90% in the nanomolar range. 4-Cyclopentylamino-7,8-dichloro-1-hydroxymethylimidazo[1,2-a]quinoxaline 18 is the most potent compound in this series, having K-i = 7 nM, which is remarkably higher than that of IRFI-165 (K-i = 48). 1-Hydroxymethyl groups of the tricyclic heteroarmatic compounds displayed the potent affinities toward A(1)AR. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.06.026
• 作为产物：
  描述：

  Tetrahydropyranylglycidol 在 ammonium hydroxide 作用下， 生成 1-氨基-3-(四氢-2H-吡喃-2-基氧基)-2-丙醇
  参考文献：
  名称：

  Compositions and methods for treating cancer

  摘要：

  这项发明涉及用于治疗或缓解癌症症状的组合物和方法。该发明的组合物和方法将超致死剂量的辐射（称为热点）直接作用于几乎所有癌细胞类型。

  公开号：

  US20060018908A1

文献信息

• Compositions and methods for treating cancer
  申请人：Mayers L. George

  公开号：US20060018908A1

  公开（公告）日：2006-01-26

  The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.

  这项发明涉及用于治疗或缓解癌症症状的组合物和方法。该发明的组合物和方法将超致死剂量的辐射（称为热点）直接作用于几乎所有癌细胞类型。
• US7615221B2
  申请人：——

  公开号：US7615221B2

  公开（公告）日：2009-11-10
• Design, synthesis, and biological evaluation of novel 4-alkylamino-1-hydroxymethylimidazo[1,2-a]quinoxalines as adenosine A1 receptor antagonists
  作者：Chun-He Liu、Bo Wang、Wei-Zhang Li、Liu-Hong Yun、Ying Liu、Rui-Bing Su、Jin Li、He Liu

  DOI：10.1016/j.bmc.2004.06.026

  日期：2004.9

  A series of 4-alkylamino-1-hydroxymethylimidazo[1,2-a]quinoxalines have been synthesized and evaluated for their adenosine A(1) receptor inhibitory activity in the radioligand binding assays. The compounds were tested for the inhibition percent (IP) and the affinity toward A(1)AR (K-i) that IP were more than 90% in the nanomolar range. 4-Cyclopentylamino-7,8-dichloro-1-hydroxymethylimidazo[1,2-a]quinoxaline 18 is the most potent compound in this series, having K-i = 7 nM, which is remarkably higher than that of IRFI-165 (K-i = 48). 1-Hydroxymethyl groups of the tricyclic heteroarmatic compounds displayed the potent affinities toward A(1)AR. (C) 2004 Elsevier Ltd. All rights reserved.